Last reviewed · How we verify
Ultra-fluid lipiodol
Ultra-fluid lipiodol is a radiopaque iodized oil suspension used as a contrast agent and embolic material for diagnostic imaging and interventional procedures.
Ultra-fluid lipiodol is a radiopaque iodized oil suspension used as a contrast agent and embolic material for diagnostic imaging and interventional procedures. Used for Diagnostic imaging in angiography and vascular procedures, Transarterial chemoembolization (TACE) for hepatocellular carcinoma, Therapeutic embolization of vascular lesions.
At a glance
| Generic name | Ultra-fluid lipiodol |
|---|---|
| Also known as | lipiodol |
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Radiopaque contrast agent / embolic material |
| Modality | Small molecule |
| Therapeutic area | Oncology / Interventional Radiology |
| Phase | Phase 3 |
Mechanism of action
Lipiodol is an ethiodized oil that contains iodine, providing radiopacity for visualization under fluoroscopy and X-ray imaging. The ultra-fluid formulation allows for improved flow characteristics and penetration into target vessels, making it suitable for both diagnostic angiography and therapeutic embolization procedures. It is commonly used in hepatocellular carcinoma treatment via transarterial chemoembolization (TACE) and other vascular interventions.
Approved indications
- Diagnostic imaging in angiography and vascular procedures
- Transarterial chemoembolization (TACE) for hepatocellular carcinoma
- Therapeutic embolization of vascular lesions
Common side effects
- Iodine hypersensitivity reaction
- Hepatic toxicity
- Vascular occlusion complications
- Postembolization syndrome
Key clinical trials
- A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures (PHASE4)
- The Cost-effectiveness of Hysterosalpingography Versus Hysterosalpingo-foam Sonography During Fertility Work-up (NA)
- The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol (PHASE2)
- Sonographic Hysterosalpingography: Oil vs Water Based Media (SHOW Trial) (PHASE4)
- Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin (PHASE1)
- Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus (PHASE3)
- A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC (PHASE3)
- Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultra-fluid lipiodol CI brief — competitive landscape report
- Ultra-fluid lipiodol updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI